本人╱吾等 （附註 1 ） 地址為 為上述公司股本中每股面值0.00001美元股份 （附註 2 ） 茲委任股東特別大會主席或 （附註 3 ） Jinxin Fertility Group Limited * 1951 適用於將於2025年12月5日舉行的股東特別大會的代表委任表格 股的登記持有人， 地址為 為本人╱吾等的受委代表出席上述公司謹訂於2025年12月5日（星期五）上午十時正假座中國四川省 成都市錦江區畢昇路66號四川錦欣西囡婦女兒童醫院畢昇院區5樓會議室3舉行的股東特別大會（「大 會」）及其任何續會，於大會（及其任何續會）上代表本人╱吾等考慮並酌情通過股東特別大會通告所 載的決議案，並按下列指示 （附註 4 ） 就決議案為本人╱吾等及以本人╱吾等名義進行投票。 | | | （附註5） 普通決議案 | （附註4） 贊成 | 反對 | （附註4） | | --- | --- | --- | --- | --- | --- | | 1. | (i) | 待香港聯合交易所有限公司（「聯交所」）上市委員 | | | | | | | 會批准因根據本公司2025年股份計劃（「2025年股 | | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited * 1951 股東特別大會通告 茲通告錦欣生殖醫療集團有限公司*（「本公司」）謹訂於2025年12月5日（星期五）上午十時 正假座中國四川省成都市錦江區畢昇路66號四川錦欣西囡婦女兒童醫院畢昇院區5樓會議 室3舉行股東特別大會（「大會」），以處理以下事項： 普通決議案 承董事會命 錦欣生殖醫療集團有限公司* * 僅供識別 - 1 - 1. 「動議： (i) 待香港聯合交易所有限公司（「聯交所」）上市委員會批准因根據本公司2025年股 份計劃（「2025年股份計劃」）可能授出的任何股份獎勵及╱或購股權（「獎勵」）歸 屬及╱或獲行使後可能須予發行及配發的本公司股份（「股份」）上市及買賣後， 謹此批准及採納2025年股份計劃，並謹此授權本公司任何董事採取一切可能屬 必要或權宜的行動及訂立一切有關交易、安排及協議，以使2025年股份計劃全 面生效，包 ...

閣下如已售出或轉讓名下所有錦欣生殖醫療集團有限公司*的股份，應立即將本通函交予買主 或承讓人或經手買賣的銀行、股票經紀或其他代理人，以便轉交買主或承讓人。 此乃要件 請即處理 閣下對本通函或應採取的行動如有任何疑問，應諮詢 閣下的股票經紀、銀行經理、律師、專 業會計師或其他專業顧問。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通函全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 1951 Jinxin Fertility Group Limited (1)建議採納2025年股份計劃 (2)有條件向執行董事授出購股權 (3)建議重選非執行董事 及 (4)股東特別大會通告 錦欣生殖醫療集團有限公司*謹訂於2025年12月5日（星期五）上午十時正假座中國四川省成都 市錦江區畢昇路66號四川錦欣西囡婦女兒童醫院畢昇院區5樓會議室3舉行股東特別大會，召開 大會的通告載於本通函第38至41頁。隨函亦附奉股東特別大會適用的代表委任表格。此代表委 任表格亦刊載於香港聯合交易所有限公司的網站(www.hkexnew ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited * 董陽 * 僅供識別 - 1 - 香港，2025年11月19日 董事會謹此宣佈，本公司謹訂於2025年12月5日（星期五）上午十時正假座中國四川省成都 市錦江區畢昇路66號四川錦欣西囡婦女兒童醫院畢昇院區5樓會議室3舉行股東特別大 會，以審議及批准建議採納2025年股份計劃、有條件向董陽先生授出購股權及重選陳樹 云先生為本公司非執行董事。為釐定股東出席股東特別大會並於會上投票的資格，本公 司將於2025年12月3日（星期三）至2025年12月5日（星期五）（包括首尾兩天）暫停辦理股份 過戶登記手續，期間將不會辦理任何股份過戶登記手續。為符合資格出席股東特別大會 並於會上投票，所有過戶文件連同有關股票須於2025年12月2日（星期二）下午四時三十分 前，送交本公司的香港證券登記處香港中央證券登記有限公司（地址為香港灣仔皇后大道 東183號合和 ...

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 4.17 million shares on November 18, 2025, bringing the total holdings to 1.45 billion shares, which represents 52.58% of the company's issued ordinary shares [1][2] Group 1: Shareholding Changes - Over the past five trading days, there were two days of net reductions in holdings by southbound funds, totaling a net decrease of 686,700 shares [1] - In the last 20 trading days, there were ten days of net increases in holdings by southbound funds, with a cumulative net increase of 8.73 million shares [1] Group 2: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment [2] - The company's services are mainly provided in China and the United States [2]

Group 1 - The core point of the news is that southbound funds have increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 1.466 million shares on November 13, 2025, with a total net increase of 4.3525 million shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net increases in holdings by southbound funds, totaling 13.1125 million shares [1] - As of now, southbound funds hold 1.448 billion shares of Jinxin Reproductive Medicine, accounting for 52.5% of the company's issued ordinary shares [1] Group 2 - The company, Jinxin Reproductive Medicine, is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Jinxin Reproductive Medicine (01951.HK), indicating a reduction in holdings on November 12, 2025, by 4.375 million shares [1] - Over the past five trading days, there were two days of net increases in holdings by southbound funds, totaling a net increase of 4.909 million shares [1] - In the last twenty trading days, there were eleven days of net increases, with a cumulative net increase of 22.877 million shares [1] Group 2 - As of November 12, 2025, southbound funds hold a total of 1.446 billion shares of Jinxin Reproductive Medicine, representing 52.44% of the company's issued ordinary shares [1] - The trading data shows fluctuations in shareholdings, with a decrease of 0.30% on November 12, 2025, and a previous decrease of 0.07% on November 11, 2025 [2] - The company primarily provides in vitro fertilization (IVF) services and operates in China and the United States, offering a range of reproductive and medical services [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 承董事會命 錦欣生殖醫療集團有限公司* Jinxin Fertility Group Limited * 1951 進一步延遲寄發通函 茲提述錦欣生殖醫療集團有限公司*（「本公司」）日期為2025年9月25日的公告，內容有關 （其中包括）建議採納2025年股份計劃及有條件向本公司董事及高級管理層授出2025年股 份計劃項下的購股權及受限制股份，及本公司日期為2025年10月20日的公告，內容有關 延遲寄發通函（統稱「該等公告」）。除另有界定者外，本公告所用詞彙與該等公告所界定 者具有相同涵義。 誠如該等公告所披露，一份載有（其中包括）建議採納2025年股份計劃及有條件向董陽先 生授出購股權連同其項下擬進行之其他交易的進一步詳情以及召開股東特別大會的通告 的通函（「該通函」）將寄發予股東。 由於本公司需要額外時間編製及落實載入該通函的若干資料，預期寄發該通函的日期將 推遲至2025年11月25日或之前。 ...

Group 1 - The Hong Kong innovative drug sector experienced a strong rally, with the Hong Kong medical ETF (159718.SZ) rising by 1.04% and net subscriptions of 3 million units during the day [1] - Notable stocks such as Jinxin Fertility (01951) increased by 5.51%, Weimaitong (02192) by 5.13%, and Shenwei Pharmaceutical (02877) by 4.45% [1] - The negotiation for the 2025 National Basic Medical Insurance Drug List and the price negotiation for commercial insurance innovative drug list was completed, with 120 domestic and foreign companies participating [1] Group 2 - The innovative drug sector sentiment has recently declined, but with ongoing business development (BD) activities, the sector's sustainability is expected to continue [2] - The current investment and financing data, orders, and performance metrics show a positive trend in the innovative drug industry chain [2] - The Hong Kong medical ETF includes a balanced composition of innovative drugs, CXO, internet healthcare, and innovative devices, making it a convenient tool for investors [2]

Core Insights - The 8th China International Import Expo (CIIE 2025) showcased over 2,800 enterprises from more than 100 countries, with a significant focus on medical technology innovations [2] - Three key trends emerged in the medical technology sector: higher global innovation density, stronger system collaboration, and deeper participation from domestic manufacturers [2] - Notable companies highlighted include Boston Scientific, Medtronic, Alcon, GE, Siemens, Intuitive Surgical, and Yuanhua Intelligent, covering a wide range of medical technologies [2] Group 1: Boston Scientific - Boston Scientific presented over 80 minimally invasive products, with six new products making their debut, including the FARAWAVE NAV catheter and AdVance XP sling [4][6] - Key innovations focus on integrated solutions for atrial fibrillation treatment, male stress urinary incontinence, and carotid artery reconstruction safety [6][7] - The company's diverse portfolio reflects a dual drive of global innovation and local manufacturing [7] Group 2: Medtronic - Medtronic showcased over 100 innovative technologies, emphasizing a systematic approach to future surgery and intelligent medical solutions [9][10] - The AiBLE™ digital innovation ecosystem was highlighted, integrating navigation, robotics, imaging, and monitoring for enhanced surgical precision [9] - Collaborations with local partners aim to enhance the adoption of smart spine surgery and laser ablation techniques [10] Group 3: Alcon - Alcon celebrated its 30th anniversary in China, presenting innovations across the entire eye health spectrum, including three new products [11][15] - Collaborations with local institutions aim to accelerate the implementation of innovative solutions in China [15] - The company announced plans for local production of its Wavelight® excimer laser surgery equipment, enhancing the domestic supply chain [15] Group 4: Intuitive Surgical - Intuitive Surgical, a consistent participant, showcased its surgical robots and digital innovations, emphasizing a patient-first approach [19] - The Da Vinci surgical system has served over 810,000 patients in China, with new systems entering the regulatory approval process [19] - The company is building a comprehensive ecosystem that integrates diagnosis, treatment, and training [20] Group 5: GE Healthcare - GE Healthcare introduced nearly 40 innovative products, including 18 new launches and 9 global debuts, focusing on advanced imaging technologies [29][31] - The Expert X quantum CT system and MR-PET technology were highlighted for their capabilities in cardiac imaging and metabolic assessment [31] Group 6: Siemens Healthineers - Siemens Healthineers emphasized its commitment to precision diagnosis and treatment for major diseases, showcasing the ARTIS icono ceiling Xpand system [35][37] - Innovations in CT and AI cardiovascular ultrasound technologies aim to enhance diagnostic efficiency and safety [37] Group 7: Abbott - Abbott presented over ten innovative products, including the AVEIR™ DR dual-chamber leadless pacemaker, addressing chronic disease management [21][24] - The company’s offerings span multiple health management areas, including cardiovascular and diabetes care [27] Group 8: Yuanhua Intelligent - Yuanhua Intelligent introduced the world's first "five-in-one" orthopedic surgical robot system, enhancing the digital workflow in orthopedic surgeries [25][28] - The system integrates various surgical procedures, marking a significant advancement in the field [28] Group 9: Other Notable Companies - Companies like Edwards Lifesciences, Johnson & Johnson, and others showcased innovative solutions in heart valve repair, minimally invasive surgery, and advanced imaging technologies [42][45][46] - The overall trend indicates a shift towards integrated systems and collaborative innovations across the medical technology landscape [66][67]